Table 2 |
|||||
|
Published studies of MSCs in CIA. |
|||||
|
Author, Year |
MSC |
Route |
Cell number |
Day of delivery |
Outcome |
|
|
|||||
|
Djouad, 2005 |
C3H10T1/2 |
iv |
106 |
0 |
- |
|
106 |
21 |
- |
|||
|
4 × 106 |
0 |
- |
|||
|
4 × 106 |
21 |
Exacerbation |
|||
|
Augello, 2007 |
BM C57/Bl/10 or GFP transgenic |
ip |
5 × 106 |
21 |
Amelioration |
|
Choi, 2008 |
BM DBA/1 |
iv |
106 |
21, 28, 35 |
Delayed onset |
|
Gonzalez, 2009 |
hAdMSC Ad DBA/1 Ad C57/Bl6 |
ip |
106 |
5 days after disease onset |
Amelioration |
|
Schurgers, 2010 |
BM DBA/1 WT or IFNγ KO |
iv or ip |
106 |
1, 16, 23 |
- |
|
|
|||||
|
Ad, adipose derived; BM, bone marrow derived; h, human; ip, intraperitoneal; iv, intravenous; KO, knock out; WT, wild type. |
|||||
|
Sullivan et al. Arthritis Research & Therapy 2012 14:R167 doi:10.1186/ar3916 |
|||||
